Regeneron, maker of the blockbuster ophthalmology medicine Eylea, has acquired an ocular biotech, the large biopharma confirmed to Endpoints News. The London-area biotech, named Oxular, was bought last month, according to board member and recently departed CEO Mark Gaffney. He posted about the deal on LinkedIn. Gaffney is now CEO of inflammation and fibrosis biotech Calluna Pharma. Regeneron had not previously announced the deal, a company spokesperson confirmed in an email. The New York-based drugmaker plans to disclose more details in its next quarterly filing, the spokesperson added.
Read the full article: Regeneron Buys London-Based Ocular Biotech //
Source: https://endpts.com/regeneron-buys-london-based-ocular-biotech